Literature DB >> 32452554

Epoxyeicosatrienoic acids inhibit the activation of NLRP3 inflammasome in murine macrophages.

Xiao-Qin Luo1,2,3, Jia-Xi Duan4,5, Hui-Hui Yang1, Chen-Yu Zhang1, Chen-Chen Sun1, Xin-Xin Guan1, Jian-Bing Xiong1, Cheng Zu1, Jia-Hao Tao1, Yong Zhou1, Cha-Xiang Guan1.   

Abstract

Epoxyeicosatrienoic acids (EETs) derived from arachidonic acid exert anti-inflammation effects. We have reported that blocking the degradation of EETs with a soluble epoxide hydrolase (sEH) inhibitor protects mice from lipopolysaccharide (LPS)-induced acute lung injury (ALI). The underlying mechanisms remain essential questions. In this study, we investigated the effects of EETs on the activation of nucleotide-binding domain leucine-rich repeat-containing receptor, pyrin domain-containing-3 (NLRP3) inflammasome in murine macrophages. In an LPS-induced ALI murine model, we found that sEH inhibitor 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl), TPPU, profoundly attenuated the pathological injury and inhibited the activation of the NLRP3 inflammasome, characterized by the reduction of the protein expression of NLRP3, ASC, pro-caspase-1, interleukin precursor (pro-IL-1β), and IL-1β p17 in the lungs of LPS-treated mice. In vitro, primary peritoneal macrophages from C57BL/6 were primed with LPS and activated with exogenous adenosine triphosphate (ATP). TPPU treatment remarkably reduced the expression of NLRP3 inflammasome-related molecules and blocked the activation of NLRP3 inflammasome. Importantly, four EETs (5,6-EET, 8,9-EET, 11,12-EET, and 14,15-EET) inhibited the activation of NLRP3 inflammasome induced by LPS + ATP or LPS + nigericin in macrophages in various degree. While the inhibitory effect of 5,6-EET was the weakest. Mechanismly, EETs profoundly decreased the content of reactive oxygen species (ROS) and restored the calcium overload in macrophages receiving LPS + ATP stimulation. In conclusion, this study suggests that EETs inhibit the activation of the NLRP3 inflammasome by suppressing calcium overload and ROS production in macrophages, contributing to the therapeutic potency to ALI.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  NLRP3 inflammasome; acute lung injury; epoxyeicosatrienoic acids; macrophages; soluble epoxide hydrolase

Mesh:

Substances:

Year:  2020        PMID: 32452554     DOI: 10.1002/jcp.29806

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  5 in total

1.  Cardiomyocyte-specific disruption of soluble epoxide hydrolase limits inflammation to preserve cardiac function.

Authors:  Deanna K Sosnowski; K Lockhart Jamieson; Artiom Gruzdev; Yingxi Li; Robert Valencia; Ala Yousef; Zamaneh Kassiri; Darryl C Zeldin; John M Seubert
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-08-19       Impact factor: 5.125

2.  COX-2/sEH Dual Inhibitor PTUPB Attenuates Epithelial-Mesenchymal Transformation of Alveolar Epithelial Cells via Nrf2-Mediated Inhibition of TGF-β1/Smad Signaling.

Authors:  Chen-Yu Zhang; Xin-Xin Guan; Zhuo-Hui Song; Hui-Ling Jiang; Yu-Biao Liu; Ping Chen; Jia-Xi Duan; Yong Zhou
Journal:  Oxid Med Cell Longev       Date:  2022-04-25       Impact factor: 7.310

3.  Fn14 exacerbates acute lung injury by activating the NLRP3 inflammasome in mice.

Authors:  Xin-Xin Guan; Hui-Hui Yang; Wen-Jing Zhong; Jia-Xi Duan; Chen-Yu Zhang; Hui-Ling Jiang; Yang Xiang; Yong Zhou; Cha-Xiang Guan
Journal:  Mol Med       Date:  2022-07-30       Impact factor: 6.376

4.  COX-2/sEH Dual Inhibitor Alleviates Hepatocyte Senescence in NAFLD Mice by Restoring Autophagy through Sirt1/PI3K/AKT/mTOR.

Authors:  Chen-Yu Zhang; Xiao-Hua Tan; Hui-Hui Yang; Ling Jin; Jie-Ru Hong; Yong Zhou; Xiao-Ting Huang
Journal:  Int J Mol Sci       Date:  2022-07-27       Impact factor: 6.208

5.  Integrated pyroptosis measurement and metabolomics to elucidate the effect and mechanism of tangzhiqing on atherosclerosis.

Authors:  Rui Chen; Ting Chen; Zhihuan Zhou; Zhihui Song; Wanying Feng; Xintong Yang; Xianliang Wang; Bin Li; Xinya Ding; Han Zhang; Yi Wang
Journal:  Front Physiol       Date:  2022-09-12       Impact factor: 4.755

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.